Claims
- 1. A protein or polypeptide having adenylate cyclase activity, said activity being regulatable by calcineurin.
- 2. A protein or polypeptide as claimed in claim 1 which is encoded by a polynucleotide comprising a nucleotide sequence derived from the sequence set out in SEQ ID NO: 1 or in SEQ ID NO: 98, or a part thereof.
- 3. A protein or polypeptide as claimed in either one of claims 1 and 2 comprising the amino acid sequence as set out in SEQ ID NO: 2 or in SEQ ID NO: 99, a functional equivalent or part thereof.
- 4. A protein or polypeptide as claimed in any one of claims 1 to 3 which includes amino acid Nos 503-570 of SEQ ID NO: 2 or which includes amino acid Nos 503-570 of SEQ ID NO: 99.
- 5. An isolated polynucleotide comprising a nucleotide sequence as set out in SEQ ID NO: 98, or a part thereof.
- 6. A recombinant polynucleotide construct comprising a polynucleotide as claimed in claim 5.
- 7. A vector comprising a polynucleotide as claimed in claim 5 or a construct as claimed in claim 6.
- 8. A host cell transformed with a vector as claimed in claim 7.
- 9. A host cell as claimed in claim 8 which is derived from the Human Embryonic Kidney Cell line 293.
- 10. The use of a regulator of a protein or polypeptide as claimed in any one of claims 1 to 4 to influence cellular metalbolism by affecting the adenylate cyclase activity or the amount of said protein or polypeptide.
- 11. The use as claimed in claim 10 wherein said regulator is calcineurin, its activators, inhibitors and competitors; antibodies to amino acids 503-570; or β-adrenergic agonists and β-adrenergic antagonists.
- 12. The use as claimed in either one of claims 10 and 11 wherein said regulator is an antibody to amino acids 503-570 of SEQ ID NOS: 2 or 99.
- 13. A method of treating a human or non-human animal body, said method comprising administrating an agent to affect the adenylate cyclase activity of, or the amount of a protein or polypeptide as claimed in any one of claims 1 to 4, said protein or polypeptide being present within said body.
- 14. A method as claimed in claim 13 wherein said protein or polypeptide is naturally present within said body.
- 15. A method as claimed in either one of claims 13 and 14 to affect or combat neurological-based disorders; psychiatrically-based disorders; endocrine-based disorders; cardiovascular-based disorders; pregnancy-based disorders; respiratory-based disorders; bone-based disorders; kidney-based disorders; gut-based disorders; or tumours.
- 16. The use of a protein or polypeptide as claimed in any one of claims 1 to 4 or a polynucleotide as claimed in claim 5 to design or test for a therapeutic agent which influences cellular metabolism.
Priority Claims (2)
Number |
Date |
Country |
Kind |
9502806.4 |
Feb 1995 |
GB |
|
9516528.8 |
Aug 1995 |
GB |
|
Parent Case Info
[0001] This Application is a continuation-in-part of U.S. Ser. No. 08/894,173, filed Aug. 13, 1997, currently pending.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09398193 |
Sep 1999 |
US |
Child |
09751100 |
Dec 2000 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
08894173 |
Aug 1997 |
US |
Child |
09398193 |
Sep 1999 |
US |
Parent |
PCT/GB96/00312 |
Feb 1996 |
US |
Child |
09398193 |
Sep 1999 |
US |